Anti-obesity therapies

Nature Reviews Drug Discovery

Volumn 5, Issue 5, 2006, Pages 369-370

  Melnikova, Irena ^a   Wages, David ^b  

^a MEDACorp   (United States)

^b ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 162352; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; AOD 9604; APD 356; ATL 962; CETILISTAT; DEXFENFLURAMINE; ESTRONE OLEATE; FEN PHEN; FENFLURAMINE; GHRELIN VACCINE; GT 389255; HUMAN GROWTH HORMONE; NON PRESCRIPTION DRUG; OXYNTOMODULIN; PEPTIDE YY 3-36; PHENDIMETRAZINE; PHENTERMINE; PRAMLINTIDE; RIMONABANT; SEROTONIN 2C AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TM 30338; UNCLASSIFIED DRUG;

AGGRESSION; ANXIETY DISORDER; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DECREASED APPETITE; DEFECATION URGENCY; DEPRESSION; DRUG ABUSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FECES INCONTINENCE; HUMAN; HYPERTENSION; NOTE; OBESITY; PRIORITY JOURNAL;

ANTI-OBESITY AGENTS; DIET; EXERCISE; HUMANS; LIPID METABOLISM; OBESITY;

EID: 33745225219     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2037     Document Type: Note

References (3)

1. Daniels, J. Obesity: America's epidemic. Am. J. Nurs. 106, 40-49 (2006).
2. Yanovski, S. Z. Pharmacotherapy for obesity - promise and uncertainty. N. Engl. J. Med. 353, 2187-2189 (2005).
3. Pi-Sunyer, F. X. et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientA: RIO-North America: a randomized controlled trial. J. Am. Med. Assoc. 295, 761-775 (2006).